1. NOACs in AF: Consequences of Underdosing and NonAdherence

3. NOACs Have Revolutionized Stroke Prevention in AF

4. Translating NOAC Trial Results Into Benefits for Patients

5. NOACs for AF: Trial Design

6. Experience With Low-Dose NOACs From the Phase 3 AF Studies

7. Approved NOAC Dosing Regimens

8. How Are NOACs Prescribed in the Real World?

9. Why Do Physicians Underdose?

10. What Are the Consequences of Underdosing?

11. Underdosing: Who Is at Increased Risk?

12. ORBIT-II AF: Outcomes After Adjustment For Inappropriate Dosing

13. Do Current Prescribing Patterns Reflect RCT Dosing?

14. How Do We Address Underdosing?

15. How Do We Address Underdosing? (cont)

16. Medication Adherence: ABC Taxonomy

17. Gold Standard Measurement of Medication Nonadherence

18. Extent of Medication Nonadherence in NVAF

19. Consequences of Medication Nonadherence

20. Pharmacokinetic Considerations Suggest That Twice-Daily Regimen Increases Forgiveness for Similar Deviations in Adherence

21. Ways to Increase Adherence

22. Summary

23. Abbreviations